Access to anti-retroviral drugs, male in Burundi

Burundi: Access to anti-retroviral drugs, male was 90.0% in 2024. ◆ Volatile

Latest (2024)
90.0%
Change on year
unchanged
World rank
13th
of 141 countries
All-time high
90.0%
in 2023
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Burundi, 2000–2024

0204060801002000201220242000: 0 %2001: 1 %2002: 1 %2003: 1 %2004: 4 %2005: 7 %2006: 8 %2007: 12 %2008: 15 %2009: 19 %2010: 25 %2011: 29 %2012: 27 %2013: 31 %2014: 36 %2015: 44 %2016: 55 %2017: 61 %2018: 70 %2019: 78 %2020: 80 %2021: 83 %2022: 84 %2023: 90 %2024: 90 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, male in Burundi is 90.0%, measured in 2024. That is the highest value across all 25 years on record.

The figure is up 150.0% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Burundi peaked at 90.0% in 2023 and was at its lowest, 0.0%, in 2000.

That places Burundi 13th out of 141 countries with data for 2024, putting it in the top 10%.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Burundi, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Burundi, 2000 to 2024.
Year % Change
2000 0.0%
2001 1.0%
2002 1.0% +0.0%
2003 1.0% +0.0%
2004 4.0% +300.0%
2005 7.0% +75.0%
2006 8.0% +14.3%
2007 12.0% +50.0%
2008 15.0% +25.0%
2009 19.0% +26.7%
2010 25.0% +31.6%
2011 29.0% +16.0%
2012 27.0% -6.9%
2013 31.0% +14.8%
2014 36.0% +16.1%
2015 44.0% +22.2%
2016 55.0% +25.0%
2017 61.0% +10.9%
2018 70.0% +14.8%
2019 78.0% +11.4%
2020 80.0% +2.6%
2021 83.0% +3.8%
2022 84.0% +1.2%
2023 90.0% +7.1%
2024 90.0% +0.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 6.8% 0.0% 19.0% 10
2010s 45.6% 25.0% 78.0% 10
2020s 85.4% 80.0% 90.0% 5

Countries ranked near Burundi

  1. 11 Botswana 92.0% compare
  2. 12 Spain 91.0% compare
  3. 13 Malawi 90.0% compare
  4. 13 Namibia 90.0% compare
  5. 13 Switzerland 90.0% compare

See the full ranking of 160 places →

More gender data for Burundi

All data for Burundi →

Frequently asked questions

What is access to anti-retroviral drugs, male in Burundi?
Access to anti-retroviral drugs, male in Burundi was 90.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Burundi?
The highest recorded value was 90.0% in 2023.
What is the lowest access to anti-retroviral drugs, male recorded in Burundi?
The lowest recorded value was 0.0% in 2000.
How does Burundi rank for access to anti-retroviral drugs, male?
Burundi ranks 13th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Burundi?
Over the last ten years it is up 150.0%. The long-run trend across the full record is volatile.
Where does this Burundi data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Burundi. Statizoid, drawing on UNAIDS estimates. Retrieved 11 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/burundi/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/burundi/">Access to anti-retroviral drugs, male in Burundi</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.